Research Roundup


20191453 - idea concept with light bulbs and energy save bulb green background

Debbie Rigby takes a look at the latest in research news

Omega-3 supplementation and cardiovascular disease

Meta-analysis of 17 RCTs shows no association between dose-specific omega-3 supplementation and CVD outcomes. Omega-3 supplementation at a dose of <2g/day was not associated with any outcome including all-cause mortality and cardiac death. evidence for higher doses (2–4 1 g capsules/day) was weak.

Heart 2020.

 

Pharmacological interventions for smoking cessation among people with schizophrenia spectrum disorders

People with schizophrenia have higher rates of smoking than the general population, and lower quit rates. This systematic review concluded that varenicline might be superior to bupropion; however, additional direct testing and combination trials of pharmacological agents for smoking cessation are required to inform clinical decision making for people with psychosis.

Lancet Psychiatry 2020.

 

Beta-blocker use and acute exacerbations of COPD following myocardial infarction

Patients with chronic obstructive pulmonary disease are undertreated with beta-blockers following myocardial infarction, possibly due to fear for acute exacerbations of COPD. In a Danish nationwide study of patients with COPD following hospitalisation for MI, beta-blocker use was not associated with increased risk of acute exacerbations of COPD following MI. This finding was independent of COPD severity, symptom burden and exacerbation history, and supports the safety of beta-blockers in patients with COPD, including high-risk patients with severe disease.

Thorax 2020.

 

Diagnosis and Management of Patients with Heart Failure with Preserved Ejection Fraction (HFpEF)

Heart failure with preserved ejection fraction (HFpEF) has no universally accepted therapies that alter the clinical course of condition. Current guidelines for the management of HFpEF focus on the treatment of underlying conditions (eg hypertension or atrial fibrillation). Diuretics are recommended for the relief of symptoms.

Therapeutics and Clinical Risk Management 2020;1:769–785.

 

Previous Doctor couldn’t say ‘no’
Next FIP gets new Aussie vice president

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.

1 Comment

  1. Geoffrey Timbs
    20/09/2020

    Re the meta analysis on Omega 3 supplementation and CVDisease, 2x 1gm capsules per day showed a statistically significant reduction of cardiac death and 3x 1gm had statistically significant reduction of cardiac death, sudden death and stroke but the study concludes the evidence is weak.
    It would seem to be an error to summarise it “shows no association between dose-specific omega-3 supplementation and CVD outcomes“ rather that there is an apparent association that needs more study

Leave a reply